Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by basslifton Jan 03, 2018 8:23am

76 Views

Post# 27268824

RE:RE:RE:RE:RE:What A P0S still stuck under .50

What seems like easy money isn’t always without stress. In any case don’t feel you need to get in at the bottom each time. Read the charts and pick an entry be confident in your decision and pull the trigger. I bought Kaly at the end of the last major run before this. I was first in at .36 and averaged down to the point where I could sell on a spike and buy back. Now in at .275 and happy with the play. This stock has great potential and is still severely beaten down compared to the 52 week high.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity